查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球小兒神經科設備市場 - 2023-2030
市場調查報告書
商品編碼
1374888

全球小兒神經科設備市場 - 2023-2030

Global Pediatric Neurology Devices Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

小兒神經病學是治療的一個專門組成部分，涉及新生兒、嬰兒、青少年和青少年神經系統疾病的檢測和管理。兒科神經科設備是用來解決青少年神經系統問題的儀器。兒科神經科設備中採用的技術是為治療神經系統疾病而開發的。

市場動態：促進因素與限制因素

產品介紹的增加

兒科神經設備進入市場的增加預計將在預測期內推動全球市場的成長。例如，2023 年7 月，尼克勞斯兒童醫院推出了新型高密度腦電圖(HD EEG) 系統和經顱磁刺激(TMS) 機，成為美國最先進的為兒科患者提供此類設備的醫院之一。

此外，2022年10月，NeuroSigma推出了用於治療兒科注意力不足/過動症（ADHD）的Monarch eTNS系統和兒科護理共付額計劃，以促進患者獲得此開發成果。此外，不斷成長的技術進步、不斷提高的意識和案例等因素預計也將有助於預測期內全球市場的成長。

設備成本高

神經科設備的高成本預計將阻礙預測期內的全球市場成長。例如，迷走神經刺激（VNS）療法是治療難治性癲癇患者的既定方法，而該設備的初始成本約為10,000美元，這又需要定期更換電池，增加了總體成本，減緩了全球市場的成長。此外，缺乏專業專家和高昂的產品開發成本等其他因素正在減緩預測期內的全球市場成長。

目錄

第 1 章：方法與範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章：定義與概述

第 3 章：執行摘要

  • 按產品類型分類
  • 按指示顯示的片段
  • 按年齡層別分類
  • 最終使用者的片段
  • 按地區分類

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 產品介紹的增加
    • 限制
      • 設備成本高
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 報銷分析
  • 專利分析
  • 科技趨勢
  • 流行病學
  • SWOT分析
  • DMI 意見

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆發前的情景
    • 新冠疫情期間的情景
    • 新冠疫情後的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商策略舉措
  • 結論

第 7 章：按產品類型

  • 神經刺激裝置
  • 神經外科設備
  • 介入性器械
  • CSF 管理設備
  • 其他產品類型

第 8 章：依指示

  • 癲癇
  • 中風
  • 腦積水
  • 神經腫瘤學適應症
  • 其他適應症

第 9 章：按年齡層

  • 0-5歲
  • 5-10年
  • 10-15歲

第 10 章：最終用戶

  • 醫院
  • 專科診所
  • 門診手術中心 (ASC)
  • 其他

第 11 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第 12 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 13 章：公司簡介

  • Abbott Laboratories
    • 公司簡介
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • LivaNova PLC
  • Medtronic PLC, Inc.
  • Natus Medical Inc.
  • Stryker Corporation
  • B.Barun SE
  • Integra LifeSciences Corporation, Inc.
  • Boston Scientific Corporation
  • NeuroSigma, Inc.
  • Zimmer Biomet

第 14 章：附錄

簡介目錄
Product Code: MD7189

Overview

Pediatric neurology is addressed as a specialized component of treatment that deals with the detection and management of neurological disorders in neonates (newborns), infants, juveniles, and adolescents. Pediatric neurology devices are the instruments that are utilized to address neurological issues in youngsters. The technology employed in pediatric neurology devices is developed for curing neurological conditions.

Market Dynamics: Drivers & Restraints

Increase in Product Introductions

The increase in pediatric neurological device introductions into the market is expected to boost the global market growth during the forecast period. For instance, in July 2023, Nicklaus Children's Hospital introduced a new high-density electroencephalogram (HD EEG) system and transcranial magnetic stimulation (TMS) machine, evolving as one of the foremost in the country to deliver this equipment for the care of pediatric individuals.

Moreover, in October 2022, NeuroSigma introduced the Monarch eTNS System for treating pediatric attention-deficit/hyperactivity disorder (ADHD) and the Pediatric Care Copay program to promote patient access to the development. Furthermore, growing technological advancements, growing awareness and cases among other factors are also expected to contribute to the global market growth during the forecast period.

High Device Cost

The high cost of neurology devices is expected to hamper the global market growth during the forecast period. For instance, Vagus nerve stimulation (VNS) therapy is an established method for treating patients with refractory seizures, while the initial cost of the device is about 10,000 US dollars which again requires regular battery changes adding to the overall cost, slowing the global market growth. Furthermore, the lack of professional specialists and high product development costs among other additional factors are slowing the global market growth in the forecast period.

Segment Analysis

The global pediatric neurology devices market is segmented based on product type, indication, age group, end user and region.

Nerve Simulation Product Type is Expected to Dominate Market

Owing to the increase in new product introductions into the segment the nerve simulation product type is expected to hold the majority of the global market share during the forecast period. For instance, in February 2021, the FDA awarded 510(k) authorization to electroCore to extend the authorization of gammaCore, the corporation's non-invasive vagus nerve stimulation, for the acute and preventative therapy of adolescent migraine. Moreover, in February 2023, LivaNova PLC, a top medical technology and innovation corporation, introduced SenTiva DUO, an implantable pulse generator (IPG) with a dual-pin header to deliver VNS Therapy in the treatment of drug-resistant epilepsy.

Geographical Analysis

North America is Expected to Dominate the Global Market

Owing to the increase in pediatric neurology device market developments in North America the region is expected to dominate the global market during the forecast period. For instance, in October 2022, NeuroSigma, Inc., a Los Angeles-based bioelectronics corporation, introduced the Monarch eTNS System the foremost medical device authorized by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD for pediatric patients (i.e., children ages 7-12), at the annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Toronto.

Also, in December 2022, Brain Scientific, a Florida-based applied science technology corporation, formed a new distribution agreement with MVAP Medical Supplies to push sales into the rapidly expanding and underserved pediatric EEG marketplace.

Further, in January 2023, NeuroSigma, Inc., a Los Angeles-based bioelectronics corporation trading external trigeminal nerve stimulation (eTNS) technology for the treatment of neurological and neuropsychiatric disorders, began a strategic digital marketing collaboration with Data360, a top provider of targeted, online marketing for the healthcare industry.

COVID-19 Impact Analysis

Various neurological manifestations have been associated with children's SARS-CoV-2 infection. It was crucial to identify and provide them with appropriate and timely treatment because they can be potentially serious and life-threatening, and some can lead to long-lasting consequences.

Different neuro-pathophysiological mechanisms were presented, but a causal relationship between SARS-CoV-2 infection and neurological manifestations stays unproven. COVID-19 affects patients with neurological diseases especially, not only by the disease itself but also by its complications and pandemic management measures, which has impacted the gbal market in a mixed way.

Market Segmentation

By Product Type

  • Neurostimulation Devices
  • Neurosurgery Devices
  • Interventional Devices
  • CSF Management Devices
  • Other Product Types

By Indication

  • Seizure
  • Stroke
  • Hydrocephalus
  • Neurooncological Indications
  • Other Indications

By Age Group

  • 0-5 Years
  • 5-10 Years
  • 10-15 Years

By End User

  • Hospital
  • Specialty Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In June 2023, Biogen Inc. launched a new SPINRAZA (nusinersen) data strived to answer critical questions for the spinal muscular atrophy (SMA) community. The data were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA.
  • In October 2022, Axoft, a neurotechnology corporation, introduced and obtained the FDA Breakthrough Device designation for its brain-machine interface (BMI) to better treat neurological disorders.
  • In October 2022, SpineX, Inc., a clinical-stage medtech corporation reported the groundbreaking results of its first in-human study in children with cerebral palsy.
  • In January 2021, Theranica, a prescribed digital therapeutics (PDT) corporation obtained the Food and Drug Administration clearance to market its Nerivio therapeutic device for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older.

Competitive Landscape

The major global players in the market include: Abbott Laboratories, LivaNova PLC, Medtronic PLC, Natus Medical Inc., Stryker Corporation, B.Barun SE, Integra Lifesciences Corporation, Boston Scientific Corporation, Zimmer Biomet and NeuroSigma, Inc. among others.

Why Purchase the Report?

  • To visualize the global pediatric neurology devices market segmentation based on product type, indication, age group, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of pediatric neurology devices market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global pediatric neurology devices market report would provide approximately 69 tables, 73 figures and 194 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Age Group
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in Product Introductions
    • 4.1.2. Restraints
      • 4.1.2.1. High Device Cost
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. Technology Trend
  • 5.8. Epidemiology
  • 5.9. SWOT Analysis
  • 5.10. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Neurostimulation Devices*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Neurosurgery Devices
  • 7.4. Interventional Devices
  • 7.5. CSF Management Devices
  • 7.6. Other Product Types

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Seizure*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Stroke
  • 8.4. Hydrocephalus
  • 8.5. Neurooncological Indications
  • 8.6. Other Indications

9. By Age Group

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.1.2. Market Attractiveness Index, By Age Group
  • 9.2. 0-5 Years*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. 5-10 Years
  • 9.4. 10-15 Years

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospital*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Ambulatory Surgical Centers (ASCs)
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Abbott Laboratories*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. LivaNova PLC
  • 13.3. Medtronic PLC, Inc.
  • 13.4. Natus Medical Inc.
  • 13.5. Stryker Corporation
  • 13.6. B.Barun SE
  • 13.7. Integra LifeSciences Corporation, Inc.
  • 13.8. Boston Scientific Corporation
  • 13.9. NeuroSigma, Inc.
  • 13.10. Zimmer Biomet

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us